A fatty acid binding protein from Fasciola hepatica induced protection in C57/BL mice from challenge infection with Schistosoma bovis.
Three strains of mice (NMRI, C57/BL, BALB/c) were each immunized with a 12 kDa purified, native Fasciola hepatica fatty acid binding protein (Fh12) and challenged percutaneously with Schistosoma bovis cercariae. C57/BL mice immunized with Fh12 had significant reductions in S. bovis worm burden recoveries (96 and 87% reductions over controls in two separate experiments). When using NMRI or BALB/c mice, Fh12 alone or in Freund's adjuvant failed to induce significant protection against S. bovis. In C57/BL mice vaccinated against Fh 12, antibodies to the IgG2a isotype, but not to the IgG1 isotype, increased by 2 weeks after the second immunization and remained high through 8 weeks of S. bovis infection. Antibodies to S. bovis increased after 4 weeks of infection. Regarding cytokine production by spleen mononuclear cells, C57/BL mice vaccinated with Fh12 in adjuvant, and having the highest protective response against challenge infection with S. bovis, had an increase of IFN-gamma production with Concanavalin A but no increase of IL-4 in similarly stimulated cells. These results suggest that the protection obtained in this group of mice is mediated by a Th1 immune response.
Abán
J L
JL
Laboratorio de Parasitología, Facultad de Farmacia, Universidad de Salamanca, Spain.
Ramajo
V
V
Arellano
J L
JL
Oleaga
A
A
Hillyer
G V
GV
Muro
A
A
D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood; D000947:Antigens, Helminth / Q000302:isolation & purification; D002352:Carrier Proteins / Q000276:immunology*; D002478:Cells, Cultured; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005210:Fasciola hepatica / Q000276:immunology*; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005260:Female; D005620:Freund's Adjuvant; D015801:Helminth Proteins / Q000276:immunology*; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000032:analysis / Q000096:biosynthesis; D015847:Interleukin-4 / Q000032:analysis / Q000096:biosynthesis; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018996:Myelin P2 Protein / Q000276:immunology*; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D009569:Nitric Oxide / Q000096:biosynthesis; D011168:Portal System / Q000469:parasitology; D012547:Schistosoma / Q000276:immunology*; D012552:Schistosomiasis / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D012756:Sheep; D013154:Spleen / Q000276:immunology; D014611:Vaccination / Q000662:veterinary
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D002352:Carrier Proteins; C082667:Fabp5 protein, mouse; C086936:Fabp7 protein, mouse; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D015801:Helminth Proteins; D018996:Myelin P2 Protein; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D015847:Interleukin-4; D009569:Nitric Oxide; D007371:Interferon-gamma; D005620:Freund's Adjuvant